QualityStocks News Alert
  The QualityStocks Daily Newsletter for Tuesday January 13th, 2009 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters


Wall Street News Alert (TRAG)


Micro Stock Profit (UDHI)


Small Cap Voice (SNRY)

The QualityStocks Daily

Proteonomix Inc. (PROT)
ZymoGenetics Inc. (ZGEN)
Keryx Biopharmaceuticals (KERX)
Versar Inc. (VSR)

China Organic Agriculture (CNOA)
FuelCell Energy Inc. (FCEL)
Geovax Labs Inc. (GOVX)


Proteonomix Inc. (PROT)

SmallCap Voice reported previously on Proteonomix Inc. (PROT) and we are highlighting the Company today here at the QualityStocks Daily Newsletter.

Headquartered in Mountainside, New Jersey, Proteonomix Inc. is a biotechnology company trading on the Pink Sheets. Their corporate focus is on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing proteins and cell therapies to treat a wide range of diseases. Proteonomix Inc. has facilities at several academic institutions.

Proteonomix is currently focusing on cosmetics, anti aging, and injury products. Their research and development program has produced over ten patent applications and they have multiple products ready to market. The Company's subsidiary Proteoderm, Inc. commercializes the product line up. In the first quarter of this year, the Company's new line of anti aging skin care products will hit the marketplace.

Proteonomix is developing a platform for the growth of contaminant-free human embryonic stem (hES) cell lines. This platform may become the backbone of future stem cell research and the Company will make this available to researchers for study. They forecast commercialization of this product in the first quarter of this year.

The Proteonomix Cord Blood Bank is another initiative the Company is undertaking. This is to meet the need for transplant grade umbilical cord blood stem cells. They are looking to collect donated cord blood samples to maintain a database of high-resolution HLA (human leukocyte antigen) typed and tested stem cells. This is to speed the matching process, and they are utilizing an affiliate network of obstetricians and hospitals to accomplish this goal.

Proteonomix's goal is to collect, process, and store cord blood units combining the concepts of autologous (storing units for the benefit of the donor) and allogeneic (storing units for use by the general population). The Company also has a goal of addressing the lack of genetic diversity in existing cord blood banks.  They will launch a marketing program to increase participation of minority groups under-represented in the pool of available stem cell units. This will allow recipients from a wide range of ethnic and racial backgrounds access to life-saving cord blood units.

On December 18, Proteonomix announced a publication in Cloning and Stem Cells Journal Volume 10 No. 4, published on November 20, 2008 by Mary Ann Liebert, Inc., of an article entitled "Cells Derived from Human Umbilical Cord Blood Support the Long-Term Growth of Undifferentiated Human Embryonic Stem Cells." The publication, authored by Xiangcan Zhan, Ph.D. et al. of The Kennedy Krieger Institute and The Johns Hopkins University, describes the utilization of umbilical cord blood components to act as feeder cells for the growth of undifferentiated embryonic stem cells. Johns Hopkins University co-invented the technology described in the study. Michael Cohen, President of Proteonomix, Inc., is the co-inventor of key components of the technology upon which this publication is based and Proteonomix has begun to commercialize this technology.

Today, Proteonomix Inc. (PROT) closed at $8.26 down $0.24 or 2.82 percent. Volume was 23,500.

ZymoGenetics Inc. (ZGEN)

Today, StockEgg.com and HotOTC.com reported on ZymoGenetics Inc. (ZGEN) and we are too here at the QualityStocks Daily Newsletter.

ZymoGenetics Inc. focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human disease. Headquartered in Seattle , Washington , the Company trades on the NASDAQ Global Market and began in 1981. They work on a defined subset of genes that they believe has the highest probability of coding for proteins with therapeutic potential.

ZymoGenetics has contributed to the discovery or development of six recombinant protein products currently marketed by other companies. The Company has a team of protein chemists and molecular and cellular biologists who work at the center of their research and development platform. These experts work to turn new protein discoveries into product candidates. ZymoGenetics has a patent portfolio of more than 300 issued or allowed U.S. patents.

The Company is developing a pipeline of proprietary product candidates. These are for clinical opportunities, including bleeding, autoimmune, and viral diseases, and cancer. ZymoGenetics is moving these into and through clinical development. The Company intends to commercialize these product candidates through internal development. They also hope to commercialize them through collaborations with partners and out-licensing of patents from their patent portfolio.

ZymoGenetics Inc. has their RECOTHROM® Thrombin, topical (Recombinant), approved by the FDA. This is a recombinant form of thrombin. Thrombin is an enzyme that stimulates the formation of blood clots. This product candidate is in development as a topical hemostat to control bleeding under a co-promotion agreement with Bayer HealthCare.

The Company's Interleukin 21 (IL-21) product is a cytokine that regulates natural killer cells and cytotoxic T-cells. It has potential applications for the treatment of cancer. This product is licensed to Novo Nordisk A/S for commercialization outside of North America . ZymoGenetics retains commercialization rights within North America Their PEG-interferon lambda (IL-29) product is a cytokine also. It is being developed as a potential treatment for patients infected with hepatitis C.

Today, Shares of ZymoGenetics Inc. rose after they signed a deal worth up to $1.12 billion with drug developer Bristol-Myers Squibb Co. The deal is to develop a hepatitis C drug. Under the deal, Bristol-Myers Squibb Co. pays $85 million up front for rights to develop the compound. They also pay a $20 million licensing fee. Additional payments could total over $1 billion. The two companies will test the drug in the United States and Europe .

ZymoGenetics Inc. (ZGEN) closed today's session at $3.93 up $0.81 or 25.96 percent. Volume was 8,711,245 shares significantly higher than the 3-month average volume of 268,103.

Keryx Biopharmaceuticals Inc. (KERX)

Today, HotOTC.com reported on Keryx Biopharmaceuticals Inc., (KERX) Bull in Advantage, Stock Egg, Knobias did earlier and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Trading on the NASDAQ Capital Market, Keryx Biopharmaceuticals Inc. focuses on the acquisition, development, and commercialization of new pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx has their corporate headquarters in New York City .

Keryx is developing Zerenex™ (ferric citrate). This oral, iron-based compound can bind to phosphate and form non-absorbable complexes.

Zerenex is in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease (ESRD). Current estimates are that there are over one million people with end stage renal disease in major markets. Due to aging populations and the global diabetes epidemic, the number of ESRDpatients is expected to almost double by 2010.

The Company is also developing KRX-0401 (perifosine). This is a new oral anti-cancer agent. It modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates several other key signal transduction pathways, including the JNK and MAPK pathways. These are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. KRX-0401 is in Phase 2 clinical development for multiple tumor types.

More than 1,700 patients have received treatment with KRX-0401 in trials in the United States and Europe . KRX-0401 does not appear to cause depression of the immune system that may lead to life threatening infections or a decrease in platelets, which may result in bleeding. Nor does it appear to cause skin rash, flu-like symptoms, or hair loss. All of these toxicities occur frequently with many of the currently available treatments for cancer. In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types.

Today, Keryx Biopharmaceuticals announced that Michael S. Weiss, their Chairman and Chief Executive Officer, will be presenting at the J.P. Morgan 27th Annual Healthcare Conference in San Francisco .

His presentation will be webcast live on Thursday, January 15 at 1:00pm PT. It will be accessible from the Investor Information page of the Keryx Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

Today, Keryx Biopharmaceuticals Inc. (KERX) closed at $0.32 up $0.09 or 39.13 percent. Volume was 3,951,449 significantly higher than the 3-month average volume of 934,356.

Versar Inc. (VSR)

Knobias reported earlier on Versar Inc. (VSR), Newsletter Advisors, Big Idea Investor did previously, and today we highlight the Company here at the QualityStocks Daily Newsletter.

Founded in 1969, Versar Inc. is an international professional services firm supporting government and industries in national defense/homeland defense programs, environmental health and safety, and infrastructure revitalization. Headquartered in Springfield , Virginia , they list on the American Stock Exchange (AMEX). They are a global project management company delivering solutions to public and private customers who also offer their expertise in classified and hazardous projects.

The company operates a set of web sites, including their corporate websites, http://www.versar.com, http://www.homelanddefense.com, and http://www.geomet.com. They also have their business-to-business (B2B) portal for homeland defense products and services at http://www.viap.com and http://www.dtaps.com. Versar offers services in program management and oversight, program management office and project management support, quality assurance / quality control, data collection and analytical services, exposure and risk assessment services, environmental sciences, and engineering.

In Homeland Defense, they serve homeland defense, emergency planning and response, and DoD counterterrorism programs. This includes personal protective equipment for chemical and biological warfare defense programs. In Infrastructure and Management Services, they concentrate their efforts on sound management of environmental compliance, remediation and clean up, as well as cultural, archaeological, and natural resources. They also support high-level peer reviews and risk assessments. For their Professional Services they provide personnel to support client programs, analyze management and policy options, and communicate technical and non-technical information.

The Company's Denver office received awarding in the last half of 2008 of a three year Indefinite Delivery/Indefinite Quantity Contract for Environmental Remediation Services and Military Munitions Response Activities for the U.S. Army Corps of Engineers, Northwest Division. The contract value is $9 million. Versar, which teamed with professional services firm, Jacobs Engineering Group, Inc., will provide military munitions response and environmental compliance and restoration services for the Army/Air Force under this contract.

Versar received awarding of a $22.4 million task order for continued Construction Management and Quality Assurance operations in Iraq . This task order will fund their international subsidiary, Versar International Assistance Projects (VIAP), to provide engineering support, construction management, and quality assurance operations in Iraq through September 2009 for the Air Force Center for Engineering and Environment.

Last Tuesday, Versar announced that they are collaborating with Court One Corporation of Norfolk , Virginia on a $1.8 million contract. This is to design and build select renovations to Building 17 at the Walter Reed Army Medical Center in Washington . D.C. To be completed in one year, the project was awarded through the U.S. Army Corps of Engineers, Baltimore District.

Versar Inc. (VSR) closed today's session at $4.30, up $0.18 or 4.37 percent. Volume was 6,115 shares for a 3-month average volume of 31,831.70 shares.

China Organic Agriculture Inc. (CNOA)

Stock Upticks, Stock Stars, Standout Stocks, SmallCap Voice, On the Market, Investment House, Street Insider, and Chart Advisors reported recently on China Organic Agriculture Inc. (CNOA) and we highlight the Company as "One to Watch" this week here at the QualityStocks Daily Newsletter.

With offices in Los Angeles , California , and Liaoning, China, China Organic Agriculture Inc. is an active trader of agricultural products in China . Trading on the OTCBB, their mission is to capitalize on China 's growing economy with the ability to acquire upscale products. China Organic Agriculture, Inc. is engaging in the organic foods revolution. They are one of the largest producers of green and organic rice in China .

Founded in 2002, China Organic Agriculture controls all aspects of the rice production process from seeds to planting, as well as, research and development and distribution. China Organic Agriculture has established their brand loyalty among China 's affluent population with high-quality, fully certified organic rice products. China Organic Agriculture is also working to establish broad distribution of several agricultural, food, and related premium products. They have an extensive distribution network throughout major cities, including Beijing , Shanghai , and Nanjing .

The Company has their 20,000 square meter processing factory, and they have a 7.1 percent share of China 's green rice market and a 3.6 percent share of the organic rice market. The Company's total combined output is 88,600 tons. For the twelve months ended December 31, 2007, the Company's revenue was $44.5 million, a 390 percent increase over $9.0 million for the comparable period of 2006. For the twelve months, ended December 31, 2007 net income was $13.5 million, a 300 percent increase over $3.4 million for the same period in 2006.

The Company announced at the end of September 2008 that they finalized the terms for their previously announced acquisition of Dalian Huiming Industry Ltd. Dalian Huiming is a major agriculture products trading company with broad distribution throughout the northeastern provinces of China . China Organic Agriculture also announced at the end of September that they sold their Jilin Songyuan City ErMaPao Green Rice Limited subsidiary for $8.7 million to Bothven Investments Limited. China Organic Agriculture is marketing their premium green and organic rice to distributors throughout China through their Ankang subsidiary.

In October, the Company announced that they would continue to diversify through acquisitions. They will also offer premium food products to mainland China , the special administrative region of Hong Kong , and other Asian countries. They are establishing themselves as a purveyor of international food products. This includes products from California wines to the aforementioned high quality rice produced in China .

Last Friday, China Organic Agriculture Inc. announced the listing of their shares on the Frankfurt Stock Exchange. They have the trading symbol 4CA. After the NYSE and NASDAQ, the Frankfurt Stock Exchange is the world's third largest organized Exchange-trading market in terms of turnover and dealings in securities.

Jinsong Li, Chief Executive Officer, said, "Gaining exposure to investors globally is a central tenet to China Organic's aggressive growth strategy. In addition to the OTCBB, this listing on one of the world's premier stock markets will open further opportunities to expand our reach and grow our shareholder base."

We're locking China Organic Agriculture Inc. (CNOA) on our radar as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Today, China Organic Agriculture Inc. (CNOA) closed trading at $0.31 up $0.01 or 3.33 percent. Volume was 53,030 for a 3-month average volume of 271,492.

FuelCell Energy Inc. (FCEL)

Today, Stock Stars reported on FuelCell Energy Inc. (FCEL) and we are highlighting the Company as well here at the QualityStocks Daily Newsletter.

Founded in 1969, FuelCell Energy Inc. develops and produces stationary fuel cell power plants for commercial, industrial, municipal, and utility customers. Their focus is to produce ultra-clean, safe, and high-efficiency fuel cells. Their "Direct FuelCell" (DFC) generates power at approximately 50 plants worldwide. Their DFC power plants have generated over 260 million kWs of power.

Headquartered in Danbury , Connecticut , FuelCell Energy Inc. trades on the NASDAQ. They are part of the Industrial Electrical Equipment business sector. Their Danbury facility is also the center for their GTAC ( Global Technical Assistance Center ). This center remotely monitors and operates more than 60 commercial fuel cell units operating at 45 sites worldwide.

The fuel cell power plants that the Company manufactures generate electricity up to two times the efficiency of traditional fossil fuel plants. They do this with virtually no air pollution. The company has a manufacturing facility in Tarrington , Connecticut , which has the capacity of producing 50MWs of fuel cells a year.

FuelCell Energy Inc. has partnerships with major power plant developers and power companies. They also collaborate with the U.S. Departments of Energy and Defense, and other government agencies to develop leading edge technologies. The company's product line consists of systems from 300kWs to 2.4 MWs, scalable up to 50MWs.

Today, FuelCell Energy Inc. announced they were awarded a contract for Phase II of the U.S. Department of Energy's Office of Fossil Energy Solid State Energy Conversion Alliance (SECA) Coal-Based Systems Cooperative Agreement. The program cost is $30.2 million. Of this, $21 million will be funded by Department of Energy. Phase II extends from January 2009 through September 2010. Phase II goal is to build a minimum 25 kilowatt (kW) solid oxide fuel cell (SOFC) stack that meets SECA-targeted requirements for performance and manufacturing cost.

FuelCell Energy Inc. (FCEL) closed trading today at $4.55 up $0.59 or 14.90 percent. Volume was 1,243,990 for a 3-month average volume of 819,084.

Geovax Labs Inc. (GOVX)

Today, Standout Stocks reported on Geovax Labs Inc. (GOVX), StockEgg.com, HotOTC.com did earlier, and we highlight the Company as well here at the QualityStocks Daily Newsletter.

GeoVax Labs Inc. is a biotechnology company with headquarters in Atlanta , Georgia . The Company's mission is to develop, manufacture, license, and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. Trading on the OTCBB, Geovax's Acquired Immunodeficiency Disease (AIDS) vaccine technology is the subject of twenty issued or filed patent applications.

The Company designed their AIDS vaccines for use in uninfected people to prevent Acquired Immunodeficiency Disease should a person ever acquire the infection. The vaccine regimen employs a two component "prime-boost strategy." Trial participants receive administering of GeoVax HIV-1 DNA vaccine. This "primes" the immune system. They then receive the second vaccine, GeoVax's HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more than 50 percent of the components of the AIDS virus (HIV-1) but cannot cause AIDS.

Geovax Labs Inc.'s AIDS vaccines may also be effective as treatment of people who already have the AIDS virus. Studies evaluating these vaccines in HIV/AIDS infected individuals are currently in the planning stage. GeoVax Labs developed their core AIDS vaccine technologies through collaborations with Emory University 's Vaccine Center , the National Institutes of Health (NIH), and The Centers for Disease Control and Prevention (CDC).

On December 1, GeoVax Labs announced that the launch of their Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America . These trials are in collaboration with The National Institutes of Health (NIH), and the HIV Vaccine Trials Network (HVTN). The Phase 2a human clinical trial will involve 150 vaccinees and 75 placebo (control) participants.

Today, Geovax Labs Inc. (GOVX) closed at $0.106 down $0.002 or 1.40 percent. Volume was 332,847 for a 3-month average volume of 334,891.


Today, HotOTC.com reported on AMDL Inc. (ADL), Wall Street Resources did recently, and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

AMDL Inc. is a specialty pharmaceutical company. Headquartered in Tustin, California, the Company's China subsidiaries' headquarters are located in Shenzhen. Together with their subsidiary Jade Pharmaceutical Inc. (JPI), AMDL Inc. engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. AMDL Inc. trades on the American Stock Exchange (AMEX).

Founded in 1987, AMDL currently has 320 employees, most of which are in China . They began as a small biotech research and development firm with their proprietary cancer diagnostic test product AMDL-ELISA DR-70® (FDP). They acquired a proprietary cancer vaccine Combination Immunogene therapy (CIT) in 2001. It was in September of 2006 that they acquired JPI to broaden their business into a multi-segmented China operation.

JPI operates two facilities. These are Jiangxi Jiezhong Pharmaceutical Co. Ltd. (JJB), in Jiangxi Province and Yanbian Yiqiao Bio-chemical Co. Ltd. (YYB), in Jilin Province . JPI makes and markets 48 products, of which 24 are JJB branded generic western drug formulations. They also have 24 YYB branded Chinese traditional medicine and nutritional products. Their best selling products are Human Placenta Tissue Injections, Domperidone, Calcium Hydrogen Phosphate and Lysine Tablets, Levofloxacin Lactate and Sodium Chloride Injections, and Glucose Solutions. The company has 51 distributors of JJB products and 67 distributors of their YYB products.

In 2007, AMDL filed with the U.S. Food & Drug Administration for clearance to market their proprietary DR-70® (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. The Company believes that the test will help monitor cancer patients throughout the course of the disease, including after primary surgery, and in determining the response to therapy. They have submitted DR-70® (FDP) ELISA for SFDA approval as a cancer-screening test in China . They are anticipating Chinese SFDA approval by the second quarter of 2009.

In 2008, AMDL Inc. received U.S. FDA approval for their DR-70 cancer diagnostic test. This is a significant step forward for the Company. It is the result of a focused effort by them to develop and gain clearance to market their proprietary tumor marker test.

In November, AMDL Inc. reported results for the third quarter ended September 30, 2008. The Company reported gross revenues of $12.4 million. This was an increase of 113 percent compared with $5.8 million in sales for the same period in 2007. Gross profits for the third quarter ended September 30, 2008 increased to $4.9 million compared to $3.6 million for the same period in 2007. Their consolidated net income for the quarter was $1.569 million or $0.10 per share (unaudited) compared to consolidated net income of $383,108 or $0.03 per share for the same period in 2007.

AMDL Inc. (ADL) closed Tuesday's trading at $1.38 up $0.18 or 15.00 percent. Volume was 286,300 for a 3-month average volume of 58,668.30.

The QualityStocks Company Corner

Hunt Gold Corp. (HGLC)
Sector 10 Inc. (SECT)

Axial Vector Energy Corp. (AXVC)
QuoteMedia, Inc. (QMCI)

Hunt Gold Corp. (HGLC)

The QualityStocks Daily Newsletter would like to spotlight Hunt Gold Corp. (HGLC) Today, Hunt Gold Corporation closed trading at $0.0001, for no change from yesterday's close. Their volume today was 131,261,983 shares extremely higher than their 3-month average volume of 1,435,980 shares.

Hunt Gold Corporation confirmed that they have commenced with the immediate staking of an additional 71 different, but adjoining, Claim Blocks surrounding their "Mockingbird" Gold Mine in Arizona.

Hunt Gold Corporation (HGLC) is a gold mining and exploration company focused on the development and exploration of their “Mockingbird,” “Ambassador,” “Golden Eagle,” “Gladstone Lookout,” “Lady Alde,” “Lookout Silver,” “Starlight,” “American Flag,” “Venezia,” “Stormcloud,” “Cherry,” “Buffalo Limecap,” “Red Cloud” and “Federal” gold properties.

The company is currently in the process of drilling on its “Mockingbird” Gold Property. The property consists of approximately 2,500 acres and is located in Mohave County, Arizona. Previous mining efforts identified the property as having the potential to hold more than a million ounces of gold resource. Hunt Gold's drilling program was initiated to verify the gold mineralization previously identified by surface sampling, and to begin building a proven or probable gold resource.

The Ambassador Gold Project is located near Prescott, Arizona in the Black Hills Mining District, which is south of the Verde Mining District and west of the Cherry Creek Mining District. Each of these districts has seen significant past production of gold, silver and copper. Well-known area mines include the United Verde, United Verde Extension, Yaeger, Monarch and Logan Mines.

The Golden Eagle property is geographically located between and on trend with the Mesquite gold mine and the Picacho gold mine. Mesquite was mined by Newmont for over 15 years and produced a total of 4MM ounces gold, while Picacho produced 388,000 ounces of gold. Past exploration by UNC focused on sampling of the underground workings of the Ambassador Mine, which showed excellent gold grades at the mine exposures and the potential for developing an economic ore deposit of over 1,000,000 ounces of gold and gold equivalent silver and copper credits. Disclaimer

Hunt Gold Corp. Daily Blog

Hunt Gold Corp. News:

Hunt Gold Corporation -- Staking of Additional Claims & the Rationale for This Expenditure

Hunt Gold Corporation -- Drilling Updates

Hunt Gold Corporation -- Stockholder Updates

Sector 10 Inc. (SECT)

The QualityStocks Daily Newsletter would like to spotlight Sector 10 Inc. (SECT) Today, Sector 10 Inc. closed trading at $0.075, which was up $0.015 or 25.00 percent from yesterday's close. Their volume today was 15,100 shares for a 3-month average volume of 31,054.70 shares.

Sector 10 Inc. is focused on becoming the world's leading provider of mobile and stationary emergency life response equipment. The company dedicates its efforts to restructuring a fragmented industry with its globally patented Mobile and Stationary Response Unit (”MRU” and “SRU”) product lines and saving lives.

While expanding its global client base, Sector 10 strives to remain rooted in its core competencies and operating principles. The company's strategy is to continue to invest in management and business development, increase efficiency, manage risk and further strengthen our culture. Sector 10 aims to reach corporate profitability and produce a favorable investment environment by establishing a balanced trend of growth and capital management.

The company is perfectly positioned to capitalize on an extremely fragmented industry and dominate its future growth. While billions of tax dollars are wasted in emergency response, little is spent on preparedness. Through Sector 10's pre-deployed solutions, immediate help and safety is available to those who need it most. These systems provide first aid supplies, life saving equipment, occupant tracking through a real-time 3D interface, and emergency communications.

Leading the way at Sector 10 is Pericles DeAvila who serves as the company's CEO, inventor and lead creative thinker. DeAvila is responsible for all strategic, financial and operational aspects of Sector 10 and its associated businesses. DeAvila studied business and construction management in California and also studied at the Institute University of the Azores. He fluently speaks Portuguese, Italian, French, Spanish, as well as English and has entrepreneurial experience nationally and internationally. Disclaimer

Axial Vector Energy Corporation (AXVC)

The QualityStocks Daily Newsletter would like to spotlight Axial Vector Energy Corp. (AXVC) Today, Axial Vector Energy Corp. closed trading at $0.15, which was up $0.01 or 7.14 percent. Their volume today was 114,590 shares. Their 3-month average volume is 109,035.

Axial Vector Energy Corporation (AXVC) a publicly traded, development-stage company providing global energy solutions, develops multi-fuel engines and generators for use primarily in military and commercial applications.

Founded in 2002, with headquarters in Portland, Oregon, Axial Vector - through a joint venture agreement with Adaptive Propulsion Systems, LLC - develops and manufactures their engines and generators with an eye toward environmental responsibility and social benefit.

Axial Vector Energy Corporation owns, develops and licenses a technologically advanced suite of internal combustion engines and electric power generation modules. The company has also developed the world's only “coreless” no iron electric motors, which consume one half the electricity of conventional electric motors.

These cutting-edge technologies are focused on fulfilling global engine and energy needs by delivering greater fuel-efficiency, cost effectiveness, versatility, and environmental sensitivity than ever before in venues from the commercial to the industrial, including the vehicular and military sectors. Disclaimer

Axial Vector Energy Corporation Blog

Axial Vector Energy Corporation News:

Axial Vector Energy Corp. Summarizes Highlights of Investor Conference Call

Axial Vector Energy Corporation Announces Investor Conference Call Hosted by Company President/CEO, Sanjai Chhaunker

Axial Vector Announces the Formation of United States Wind Power Industry Joint Venture

QuoteMedia, Inc. (QMCI)

The QualityStocks Daily Newsletter would like to spotlight QuoteMedia Inc. (QMCI). Today, QuoteMedia Inc. Inc. closed trading at $0.079, which was up $0.001 or 1.28 percent. Their volume today was 22,296 shares. Their 3-month average volume is 22,273.40 shares.

QuoteMedia, Inc. (QMCI) is a leading data provider of financial stock market data , market news feeds, and related financial software solutions to financial service companies, online brokerages, clearing firms, banks and public corporations.

The Company's diversity of technical expertise, its agile responsiveness to custom corporate requirements, and its proven commitment to superior delivery technologies have established QuoteMedia as a frontrunner in the financial market data industry.

QuoteMedia, Inc's low cost data provision contracts, combined with other factors such as the Company's uniquely streamlined, cost-effective and proprietary data delivery systems, provide healthy margins even at the wholesale level. Most of QuoteMedia's competitors use outdated data delivery technologies based on legacy style data networks that incur more bandwidth, heavier server and network loads, higher server costs, and higher data delivery costs. Disclaimer

QuoteMedia, Inc. Daily Blog

QuoteMedia, Inc. News:

QuoteMedia Reports 26% Increase in Revenue for Q3 2008; and 33% Increase for Comparative 9 Month Period

QuoteMedia Reports 30% Increase in Revenue for Q2 2008

QuoteMedia Announces Enterprise Agreement with Penson Worldwide


Daily Video
Get the latest market news every weekday at 11am EST with QualityStocks.net anchors Cathy Rankin, Vanessa Ramirez and Jenn Hoffman.

Sponsors of the Day

The QualityStocks Public Company Sponsor News


QualityStocks By The Numbers Report




About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-308-0703